ENWEI PHARMACEUTICAL(301331.SZ)

ENWEI PHARMACEUTICAL: Vice President completes a reduction of 0.0157%

ENWEI PHARMACEUTICAL announced that Vice President Chen Lei has reduced his holdings in the company by 16,200 shares through centralized bidding on August 26, 2025, at an average price of 38.65 yuan/share, representing a reduction ratio of 0.0157%; after the reduction, he holds 48,918 shares, accounting for 0.0475% of the total share capital

The A-share traditional Chinese medicine sector rapidly surged, with Xintian Pharma hitting the limit up, and YIBAI PHARMACEUTICAL, Zhendong Pharmacy, ZHONGSHENGYAOYE, Hansen Pharmaceutical, and ENWEI PHARMACEUTICAL following suit

ENWEI PHARMACEUTICAL: Vice President plans to reduce holdings by 0.0158% of shares

ENWEI PHARMACEUTICAL announced that the company's vice president Chen Lei holds 65,118 shares, accounting for 0.0633% of the company's total share capital and 0.0644% of the total share capital after excluding repurchased shares. He plans to reduce his holdings by no more than 16,279 shares through centralized bidding within three months after the 15 trading days following the announcement of this reduction plan, accounting for 0.0158% of the company's total share capital and 0.0161% of the total share capital after excluding repurchased shares. The shares to be reduced come from equity incentive grants, and the reduction price will be determined based on the market price at the time of implementation

ENWEI PHARMACEUTICAL: Chengdu Jiewei has cumulatively increased its holdings in the company by 199,100 shares

ENWEI PHARMACEUTICAL announced that its controlling shareholder's concerted actor Chengdu Jiewei will increase its holdings of the company's shares by 199,100 shares through centralized bidding by May 7, 2025, raising its shareholding ratio from 67.83% to 68.02%

ENWEI PHARMACEUTICAL released its 2024 annual performance, with a net profit attributable to the parent company of 37.4975 million yuan, a year-on-year decrease of 56.56%

ENWEI PHARMACEUTICAL released its 2024 annual report, with operating revenue of 812 million yuan, a year-on-year increase of 3.43%; net profit attributable to the parent company of 37.4975 million yuan, a year-on-year decrease of 56.56%; net profit excluding non-recurring gains and losses of 34.7296 million yuan, a year-on-year decrease of 52.80%; basic earnings per share of 0.3728 yuan/share. The company plans to distribute a cash dividend of 1.80 yuan (including tax) for every 10 shares